Meeting Newsroom

FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
Ibrutinib Plus Chemoimmunotherapy Approved by European Commission for Patients With Previously Untreated MCL: TRIANGLE Trial
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with current standard of care.
Back to top